Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-503-6500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.90 million
Profitability
Miscellaneous
Employees55
OptionableOptionable
Curis (NASDAQ:CRIS) Frequently Asked Questions
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
When did Curis' stock split? How did Curis' stock split work?
Shares of Curis reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.09. The biotechnology company had revenue of $2.85 million for the quarter, compared to analysts' expectations of $2.38 million. Curis had a negative net margin of 316.98% and a negative return on equity of 299.20%. View Curis' Earnings History.
When is Curis' next earnings date?
What price target have analysts set for CRIS?
3 equities research analysts have issued 12-month target prices for Curis' stock. Their predictions range from $8.00 to $30.00. On average, they anticipate Curis' stock price to reach $19.00 in the next year. This suggests a possible upside of 1,537.9% from the stock's current price. View Analyst Price Targets for Curis.
What is the consensus analysts' recommendation for Curis?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Curis.
Has Curis been receiving favorable news coverage?
Press coverage about CRIS stock has been trending neutral this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Curis earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of Curis' key competitors?
Some companies that are related to Curis include Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Neon Therapeutics (NTGN), Surface Oncology (SURF), Pluristem Therapeutics (PSTI), Jounce Therapeutics (JNCE), Organovo (ONVO), Champions Oncology (CSBR), Nantkwest (NK), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX), Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), AVITA MED LTD/S (AVMXY) and BioCardia (BCDA).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- Mr. James E. Dentzer, Pres, CEO, COO, CFO, Chief Admin. Officer & Director (Age 52)
- Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 67)
- Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)
- Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
- Dr. Tania Chander, VP of Product Devel. & Program Management
How do I buy shares of Curis?
Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of CRIS stock can currently be purchased for approximately $1.16.
How big of a company is Curis?
Curis has a market capitalization of $38.41 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.
What is Curis' official website?
How can I contact Curis?
Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]
MarketBeat Community Rating for Curis (NASDAQ CRIS)
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
